TGFBR2 and diabetic cardiomyopathy: A study led by Meng revealed that SIL ameliorates myocardium fibrosis in rats with diabetic cardiomyopathy by inhibiting TGF-β1/Smad signaling, which is involved in TGFβR1 and TGFβR2 expression activation [92].